CSL Behring Limits Bern Job Cuts Below Early Estimates

CSL Behring has completed a major restructuring program at its Bern operations, announcing that workforce reductions were lower than originally anticipated despite months of uncertainty surrounding one of Switzerland’s largest pharmaceutical manufacturing sites.

The Australian-owned biotechnology company said its transformation initiative has concluded with job losses remaining below ten percent of the local workforce, a figure that falls beneath the estimates that circulated earlier this year when the restructuring plans first became public. The outcome provides a measure of relief for employees and regional officials who had been bracing for deeper cuts at a facility that plays a significant role in Switzerland’s pharmaceutical sector.

The Bern site, located in the Wankdorf district, is one of the company’s most important global production centers. Earlier reports suggested that approximately 180 positions could be eliminated as part of a broader cost-reduction strategy initiated by parent company CSL Limited. At the time, the company confirmed that job reductions were planned but declined to specify how many positions would ultimately be affected.

In its latest update, CSL Behring said the restructuring process has been completed and that the organization has strengthened its long-term competitiveness while preparing the Bern operation for future growth. Company representatives stated that more than 100 new positions were created during the transition, enabling many employees to move into different roles within the organization rather than leave the company altogether.

While executives declined to provide an exact figure for the final number of eliminated positions, company officials confirmed that the total remained below the previously reported estimate of around 180 jobs. The company also indicated that no additional workforce reduction rounds are currently planned for the Bern facility.

The restructuring effort has been closely watched across Switzerland’s life sciences industry, which has faced increasing pressure from global competition, changing market conditions and corporate efficiency programs. Pharmaceutical and biotechnology companies worldwide have spent the past two years reviewing operations, consolidating research activities and reducing costs in response to shifting investor expectations and slower growth in some therapeutic markets.

For CSL, the workforce review formed part of a broader transformation initiative announced by the parent company. CSL Limited previously disclosed plans to reduce its global workforce by as much as 15 percent while implementing measures designed to improve profitability and streamline operations across multiple business units. The company cited the need to strengthen long-term performance after facing earnings pressure, restructuring costs and market challenges.

The Bern operation has long been one of the company’s most strategically important locations. According to corporate disclosures, Switzerland hosts major manufacturing, research and development, and business operations for CSL Behring and related divisions. The company employs thousands of people across its Swiss activities and generates substantial revenue through products used to treat rare and serious medical conditions.

Earlier phases of the restructuring generated concern among employees, particularly after reports emerged that research and development activities in Bern would be reorganized and partially integrated with operations elsewhere in Switzerland. Labor representatives and workers sought greater clarity regarding the future of specific departments, while local authorities monitored the consultation process required under Swiss employment regulations.

Swiss labor law requires formal consultation procedures when companies above certain workforce thresholds plan significant layoffs. Because the Bern facility employs far more than 300 workers, the company was obligated to enter a consultation process once projected reductions exceeded the legal trigger point. That process allowed employees and representatives to propose alternatives aimed at limiting dismissals and preserving jobs where possible.

Industry analysts note that the final outcome appears less severe than many initially expected. The creation of new positions alongside the restructuring suggests the company’s objective was not simply workforce reduction but also a reallocation of resources toward areas considered strategically important for future growth. Such transformations have become increasingly common across the pharmaceutical sector as companies invest in advanced manufacturing technologies, automation and specialized therapies.

The announcement arrives as CSL attempts to restore growth momentum following a challenging period for parts of its global business. Recent corporate updates have pointed to signs of recovery in key product segments, particularly within plasma-derived therapies, which remain central to the company’s long-term strategy. Executives have expressed confidence that restructuring measures undertaken during the past year will contribute to stronger operational performance moving forward.

For Bern, the conclusion of the restructuring removes a major source of uncertainty that has hung over the workforce for months. Although jobs have been lost, the final scale of reductions appears lower than many employees feared when reports of possible cuts first surfaced earlier this year.

The outcome also reinforces the continuing importance of Switzerland as a hub for advanced pharmaceutical manufacturing. While global competition and corporate restructuring remain realities for the sector, CSL Behring’s decision to maintain a substantial presence in Bern underscores the strategic value of the region’s skilled workforce, infrastructure and biotechnology expertise. As the company shifts its focus from restructuring to growth, attention will now turn to whether those investments can strengthen both its competitive position and its long-term commitment to Switzerland.